The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome
The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome, Published online: 13 August 2018; doi:10.1038/s41408-018-0115-2The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 13, 2018 Category: Hematology Authors: Yi-Tsung Yang Yu-Chiao Chiu Chein-Jun Kao Hsin-An Hou Chien-Chin Lin Cheng-Hong Tsai Mei-Hsuan Tseng Wen-Chien Chou Hwei-Fang Tien Source Type: research

RBFOX2 and alternative splicing in B-cell lymphoma
RBFOX2 and alternative splicing in B-cell lymphoma, Published online: 10 August 2018; doi:10.1038/s41408-018-0114-3RBFOX2 and alternative splicing in B-cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 10, 2018 Category: Hematology Authors: Hilmar Quentmeier Claudia Pommerenke Stephan H. Bernhart Wilhelm G. Dirks Vivien Hauer Steve Hoffmann Stefan Nagel Reiner Siebert Cord C. Uphoff Margarete Zaborski Hans G. Drexler Source Type: research

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21), Published online: 07 August 2018; doi:10.1038/s41408-018-0116-1Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21) (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 7, 2018 Category: Hematology Authors: Ya-Zhen Qin Hong-Hu Zhu Qian Jiang Lan-Ping Xu Hao Jiang Yu Wang Xiao-Su Zhao Yan-Rong Liu Xiao-Hui Zhang Kai-Yan Liu Xiao-Jun Huang Source Type: research

Multiple myeloma: family history and mortality in second primary cancers
Multiple myeloma: family history and mortality in second primary cancers, Published online: 07 August 2018; doi:10.1038/s41408-018-0108-1Multiple myeloma: family history and mortality in second primary cancers (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 7, 2018 Category: Hematology Authors: Subhayan Chattopadhyay Hongyao Yu Amit Sud Jan Sundquist Asta F örsti Akseli Hemminki Kari Hemminki Source Type: research

History of autoimmune conditions and lymphoma prognosis
History of autoimmune conditions and lymphoma prognosis, Published online: 01 August 2018; doi:10.1038/s41408-018-0105-4History of autoimmune conditions and lymphoma prognosis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 1, 2018 Category: Hematology Authors: Geffen Kleinstern Matthew J. Maurer Mark Liebow Thomas M. Habermann Jean L. Koff Cristine Allmer Thomas E. Witzig Grzegorz S. Nowakowski Ivana N. Micallef Patrick B. Johnston David J. Inwards Carrie A. Thompson Andrew L. Feldman Brian K. Link Christopher Source Type: research

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort
Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort, Published online: 01 August 2018; doi:10.1038/s41408-018-0111-6Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - August 1, 2018 Category: Hematology Authors: Elodie Bohers Pierre-Julien Viailly St éphanie Becker Vinciane Marchand Philippe Ruminy Catherine Maingonnat Philippe Bertrand Pascaline Etancelin Jean-Michel Picquenot Vincent Camus Anne-Lise Menard Emilie Lemasle Nathalie Contentin St éphane Leprêtre Source Type: research

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma, Published online: 31 July 2018; doi:10.1038/s41408-018-0104-5Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 31, 2018 Category: Hematology Authors: Dharshan Sivaraj Michael M Green Yubin Kang Gwynn D Long David A Rizzieri Zhiguo Li Anderson H Garrett Jackie L McIntyre Nelson J Chao Cristina Gasparetto Source Type: research

Myelofibrosis Treatment Algorithm 2018
Myelofibrosis Treatment Algorithm 2018, Published online: 31 July 2018; doi:10.1038/s41408-018-0109-0Myelofibrosis Treatment Algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 31, 2018 Category: Hematology Authors: Ayalew Tefferi Paola Guglielmelli Animesh Pardanani Alessandro M. Vannucchi Source Type: research

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma, Published online: 30 July 2018; doi:10.1038/s41408-018-0106-3Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 30, 2018 Category: Hematology Authors: Shaji K. Kumar Francis K. Buadi Betsy LaPlant Alese Halvorson Nelson Leung Prashant Kapoor David Dingli Morie A. Gertz Ronald S. Go P. Leif Bergsagel Yi Lin Angela Dispenzieri Yi Lisa Hwa Amie Fonder Miriam Hobbs Rafael Fonseca Suzanne R. Hayman A. Keith Source Type: research

Clonal hematopoiesis in patients with rheumatoid arthritis
Clonal hematopoiesis in patients with rheumatoid arthritis, Published online: 26 July 2018; doi:10.1038/s41408-018-0107-2Clonal hematopoiesis in patients with rheumatoid arthritis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 26, 2018 Category: Hematology Authors: Paula Savola Sofie Lundgren Mikko A. I. Ker änen Henrikki Almusa Pekka Ellonen Marjatta Leirisalo-Repo Tiina Kelkka Satu Mustjoki Source Type: research

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia, Published online: 19 July 2018; doi:10.1038/s41408-018-0103-6High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 19, 2018 Category: Hematology Authors: Miriam Marquis Cyrielle Beaubois Vincent-Philippe Lavall ée Michal Abrahamowicz Coraline Danieli S ébastien Lemieux Imran Ahmad Andrew Wei Stephen B. Ting Shaun Fleming Anthony Schwarer David Grimwade William Grey Robert K. Hills Paresh Vyas Nigel Russe Source Type: research

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials, Published online: 06 July 2018; doi:10.1038/s41408-018-0102-7Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 6, 2018 Category: Hematology Authors: Sikander Ailawadhi Susanna Jacobus Rachael Sexton Alexander K. Stewart Angela Dispenzieri Mohamad A. Hussein Jeffrey A. Zonder John Crowley Antje Hoering Bart Barlogie Robert Z. Orlowski S. Vincent Rajkumar Source Type: research

Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients, Published online: 05 July 2018; doi:10.1038/s41408-018-0099-yTumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - July 5, 2018 Category: Hematology Authors: B. Manfroi J. Moreaux C. Righini F. Ghiringhelli N. Sturm B. Huard Source Type: research

Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms, Published online: 26 June 2018; doi:10.1038/s41408-018-0101-8Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 26, 2018 Category: Hematology Authors: Valerio De Stefano Guido Finazzi Tiziano Barbui Source Type: research

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018, Published online: 26 June 2018; doi:10.1038/s41408-018-0100-9Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 26, 2018 Category: Hematology Authors: Guido Finazzi Valerio De Stefano Tiziano Barbui Source Type: research

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies, Published online: 26 June 2018; doi:10.1038/s41408-018-0097-0CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 26, 2018 Category: Hematology Authors: Ayed O. Ayed Annalisa Chiappella Levi Pederson Betsy R. Laplant Angela Giovanna Congiu Gianluca Gaidano Michele Spina Alessandro Re Federica Cavallo Gerardo Musuraca William R. Macon Thomas Witzig Umberto Vitolo Grzegorz S. Nowakowski Source Type: research

NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways
NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways, Published online: 25 June 2018; doi:10.1038/s41408-018-0098-zNS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 25, 2018 Category: Hematology Authors: Ayumi Honda Kazuya Kuramoto Tomoko Niwa Haruna Naito Source Type: research

Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance, Published online: 15 June 2018; doi:10.1038/s41408-018-0093-4Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 15, 2018 Category: Hematology Authors: Jingru Zhang Yingqiao Wang Jianxiang Wang Jianda Hu Suning Chen Jie Jin Ting Liu Jianfeng Zhou Yu Hu Daoxin Ma Xiaojun Huang Chunyan Ji Ming Hou Source Type: research

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay, Published online: 12 June 2018; doi:10.1038/s41408-018-0089-0Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 12, 2018 Category: Hematology Authors: Andrew M. Intlekofer Erel Joffe Connie L. Batlevi Patrick Hilden Jie He Venkatraman E. Seshan Andrew D. Zelenetz M. Lia Palomba Craig H. Moskowitz Carol Portlock David J. Straus Ariela Noy Steven M. Horwitz John F. Gerecitano Alison Moskowitz Paul Hamlin Source Type: research

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria, Published online: 12 June 2018; doi:10.1038/s41408-018-0077-4Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 12, 2018 Category: Hematology Authors: Arjun Lakshman S. Vincent Rajkumar Francis K. Buadi Moritz Binder Morie A. Gertz Martha Q. Lacy Angela Dispenzieri David Dingli Amie L. Fonder Suzanne R. Hayman Miriam A. Hobbs Wilson I. Gonsalves Yi Lisa Hwa Prashant Kapoor Nelson Leung Ronald S. Go Yi L Source Type: research

Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients
Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients, Published online: 12 June 2018; doi:10.1038/s41408-018-0092-5Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 12, 2018 Category: Hematology Authors: In-Cheol Baek Dong-Hwan Shin Eun-Jeong Choi Hyoung-Jae Kim Jae-Ho Yoon Byung-Sik Cho Yoo-Jin Kim Seok Lee Woo-Sung Min Hee-Je Kim Tai-Gyu Kim Source Type: research

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea, Published online: 11 June 2018; doi:10.1038/s41408-018-0091-6Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 11, 2018 Category: Hematology Authors: Rossella Renso Andrea Aroldi Pietro Pioltelli Carlo Gambacorti-Passerini Elena Maria Elli Source Type: research

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?, Published online: 11 June 2018; doi:10.1038/s41408-018-0081-8Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 11, 2018 Category: Hematology Authors: Amer M. Zeidan Maximilian Stahl Michelle DeVeaux Smith Giri Scott Huntington Nikolai Podoltsev Rong Wang Xiaomei Ma Amy J. Davidoff Steven D. Gore Source Type: research

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis, Published online: 11 June 2018; doi:10.1038/s41408-018-0095-2Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 11, 2018 Category: Hematology Authors: Mythri Mudireddy Naseema Gangat Curtis A. Hanson Rhett P. Ketterling Animesh Pardanani Ayalew Tefferi Source Type: research

Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state
Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state, Published online: 07 June 2018; doi:10.1038/s41408-018-0094-3Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 7, 2018 Category: Hematology Authors: Wen-Yan Cheng Yong-Mei Zhu Zhao Liu Xiang-Qin Weng Jing-Ni Sui Yun-Shuo Chen Shi-Yang Wang Yang Shen Source Type: research

Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization, Published online: 07 June 2018; doi:10.1038/s41408-018-0096-1Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 7, 2018 Category: Hematology Authors: Stefan Hohaus Maria Chiara Tisi Francesca Bartolomei Annarosa Cuccaro Elena Maiolo Eleonora Alma Francesco D ’Alò Silvia Bellesi Elena Rossi Valerio De Stefano Source Type: research

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting, Published online: 01 June 2018; doi:10.1038/s41408-018-0078-3The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - June 1, 2018 Category: Hematology Authors: Valerio De Stefano Bianca Rocca Alberto Tosetto Denise Soldati Giovanna Petrucci Eloise Beggiato Irene Bertozzi Silvia Betti Giuseppe Carli Monica Carpenedo Daniele Cattaneo Viviana Cavalca Alfredo Dragani Elena Elli Guido Finazzi Alessandra Iurlo Giusepp Source Type: research

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis, Published online: 24 May 2018; doi:10.1038/s41408-018-0086-3Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 24, 2018 Category: Hematology Authors: Efstathios Kastritis Ioannis V. Kostopoulos Evangelos Terpos Bruno Paiva Despina Fotiou Maria Gavriatopoulou Nikolaos Kanellias Dimitrios C. Ziogas Maria Roussou Magdalini Migkou Evangelos Eleutherakis-Papaiakovou Ioannis P. Trougakos Ourania Tsitsilonis Source Type: research

Myelodysplastic syndromes current treatment algorithm 2018
Myelodysplastic syndromes current treatment algorithm 2018, Published online: 24 May 2018; doi:10.1038/s41408-018-0085-4Myelodysplastic syndromes current treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 24, 2018 Category: Hematology Authors: David P. Steensma Source Type: research

The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition
The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition, Published online: 24 May 2018; doi:10.1038/s41408-018-0082-7The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 24, 2018 Category: Hematology Authors: Shira Kahlon Dorin Shreibman Tamar Unger Dina Ben-Yehuda Shlomo Elias Source Type: research

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018, Published online: 23 May 2018; doi:10.1038/s41408-018-0080-9Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 23, 2018 Category: Hematology Authors: Morie A. Gertz Source Type: research

RTK-RAS pathway mutation is enriched in myeloid sarcoma
RTK-RAS pathway mutation is enriched in myeloid sarcoma, Published online: 23 May 2018; doi:10.1038/s41408-018-0083-6RTK-RAS pathway mutation is enriched in myeloid sarcoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 22, 2018 Category: Hematology Authors: Mihong Choi Yoon Kyung Jeon Choong-Hyun Sun Hong-Seok Yun Junshik Hong Dong-Yeop Shin Inho Kim Sung-Soo Yoon Youngil Koh Source Type: research

Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial
Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial, Published online: 22 May 2018; doi:10.1038/s41408-018-0084-5Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 22, 2018 Category: Hematology Authors: J érôme Paillassa Thibaut Leguay Xavier Thomas Fran çoise Huguet Marie Audrain V éronique Lheritier Christine Vianey-Saban C écile Acquaviva-Bourdain C écile Pagan Herv é Dombret Norbert Ifrah Nicolas Boissel Mathilde Hunault-Berger Source Type: research

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma, Published online: 11 May 2018; doi:10.1038/s41408-018-0075-6Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 11, 2018 Category: Hematology Authors: Evangelos Terpos Ioannis Ntanasis-Stathopoulos Dimitrios Christoulas Tina Bagratuni Marios Bakogeorgos Maria Gavriatopoulou Evangelos Eleutherakis-Papaiakovou Nikolaos Kanellias Efstathios Kastritis Meletios A. Dimopoulos Source Type: research

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study, Published online: 01 May 2018; doi:10.1038/s41408-018-0071-xDaratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 1, 2018 Category: Hematology Authors: Kenshi Suzuki Meletios A. Dimopoulos Naoki Takezako Shinichiro Okamoto Atsushi Shinagawa Morio Matsumoto Hiroshi Kosugi Sung-Soo Yoon Shang-Yi Huang Xiang Qin Ming Qi Shinsuke Iida Source Type: research

Waldenström macroglobulinemia treatment algorithm 2018
Waldenström macroglobulinemia treatment algorithm 2018Waldenström macroglobulinemia treatment algorithm 2018, Published online: 01 May 2018; doi:10.1038/s41408-018-0076-5Waldenström macroglobulinemia treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 1, 2018 Category: Hematology Authors: Morie A. Gertz Source Type: research

DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line
DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line, Published online: 04 April 2018; doi:10.1038/s41408-018-0072-9DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 4, 2018 Category: Hematology Authors: David Chen Matthew Christopher Nichole M. Helton Ian Ferguson Timothy J. Ley David H. Spencer Source Type: research

Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome, Published online: 04 April 2018; doi:10.1038/s41408-018-0074-7Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 4, 2018 Category: Hematology Authors: Hsin-An Hou Cheng-Hong Tsai Chien-Chin Lin Wen-Chien Chou Yuan-Yeh Kuo Chieh-Yu Liu Mei-Hsuan Tseng Yen-Ling Peng Ming-Chih Liu Chia-Wen Liu Xiu-Wen Liao Liang-In Lin Ming Yao Jih-Luh Tang Hwei-Fang Tien Source Type: research

Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome
Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome, Published online: 04 April 2018; doi:10.1038/s41408-018-0073-8Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - April 4, 2018 Category: Hematology Authors: Hao Zhao Hao Cai Chen Wang Xu-fei Huang Xin-xin Cao Lu Zhang Dao-bin Zhou Jian Li Source Type: research

miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia
miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia, Published online: 21 March 2018; doi:10.1038/s41408-018-0070-ymiR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 21, 2018 Category: Hematology Authors: Rosanna H. E. Krakowsky Alexander A. Wurm Dennis Gerloff Christiane Katzerke Daniela Br äuer-Hartmann Jens-Uwe Hartmann Franziska Wilke Christian Thiede Carsten M üller-Tidow Dietger Niederwieser Gerhard Behre Source Type: research

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients, Published online: 21 March 2018; doi:10.1038/s41408-018-0069-4Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 21, 2018 Category: Hematology Authors: Bei Jia Liru Wang David F. Claxton W Christopher Ehmann Witold B. Rybka Shin Mineishi Syed Rizvi Hiroko Shike Michael Bayerl Todd D. Schell Raymond J. Hohl Hong Zheng Source Type: research

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5
A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5, Published online: 21 March 2018; doi:10.1038/s41408-018-0062-yA multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 21, 2018 Category: Hematology Authors: Brian S. White Irena Lanc Julie O ’Neal Harshath Gupta Robert S. Fulton Heather Schmidt Catrina Fronick Edward A. Belter Jr. Mark Fiala Justin King Greg J. Ahmann Mary DeRome Elaine R. Mardis Ravi Vij John F. DiPersio Joan Levy Daniel Auclair Michael H. Source Type: research

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma
The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma, Published online: 20 March 2018; doi:10.1038/s41408-018-0066-7The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 20, 2018 Category: Hematology Authors: Shengjian Huang Changying Jiang Hui Zhang Taylor Bell Hui Guo Yang Liu Yixin Yao Dongfeng Zeng Makhdum Ahmed Krystle Nomie Leo Zhang Michael Wang Source Type: research

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms, Published online: 12 March 2018; doi:10.1038/s41408-018-0057-8Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 12, 2018 Category: Hematology Authors: Terra L. Lasho Rangit Vallapureddy Christy M. Finke Abhishek Mangaonkar Naseema Gangat Rhett Ketterling Ayalew Tefferi Mrinal M. Patnaik Source Type: research

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group, Published online: 09 March 2018; doi:10.1038/s41408-018-0059-6Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 9, 2018 Category: Hematology Authors: Eirini Katodritou Evangelos Terpos Sossana Delimpasi Maria Kotsopoulou Eurydiki Michalis Chrysanthi Vadikolia Marie-Christine Kyrtsonis Argiris Symeonidis Nikolaos Giannakoulas Chrissa Vadikolia Michalis Michael Christina Kalpadakis Theodora Gougopoulou C Source Type: research

A systematic classification of death causes in multiple myeloma
A systematic classification of death causes in multiple myeloma, Published online: 08 March 2018; doi:10.1038/s41408-018-0068-5A systematic classification of death causes in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 8, 2018 Category: Hematology Authors: Elias K. Mai Eva-Maria Haas Stephan L ücke Martin L öpprich Christina Kunz Maria Pritsch Petra Knaup-Gregori Marc S. Raab Jana Schlenzka Uta Bertsch Jens Hillengass Hartmut Goldschmidt Source Type: research

Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders
Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders, Published online: 07 March 2018; doi:10.1038/s41408-018-0061-zDetailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 7, 2018 Category: Hematology Authors: Julie Schanz Naciye Cevik Christa Fonatsch Friederike Braulke Katayoon Shirneshan Ulrike Bacher Detlef Haase Source Type: research

Momelotinib therapy for myelofibrosis: a 7-year follow-up
Momelotinib therapy for myelofibrosis: a 7-year follow-up, Published online: 07 March 2018; doi:10.1038/s41408-018-0067-6Momelotinib therapy for myelofibrosis: a 7-year follow-up (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 7, 2018 Category: Hematology Authors: Ayalew Tefferi Daniela Barraco Terra L. Lasho Sahrish Shah Kebede H. Begna Aref Al-Kali William J. Hogan Mark R. Litzow Curtis A. Hanson Rhett P. Ketterling Naseema Gangat Animesh Pardanani Source Type: research

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms, Published online: 28 February 2018; doi:10.1038/s41408-018-0048-9Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 28, 2018 Category: Hematology Authors: Valerio De Stefano Alessandra Carobbio Vincenzo Di Lazzaro Paola Guglielmelli Alessandra Iurlo Maria Chiara Finazzi Elisa Rumi Francisco Cervantes Elena Maria Elli Maria Luigia Randi Martin Griesshammer Francesca Palandri Massimiliano Bonifacio Juan-Carlo Source Type: research

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies
Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies, Published online: 28 February 2018; doi:10.1038/s41408-018-0065-8Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 28, 2018 Category: Hematology Authors: Praful Ravi Shaji K. Kumar James R. Cerhan Matthew J. Maurer David Dingli Stephen M. Ansell S. Vincent Rajkumar Source Type: research